RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
46 hedge funds and large institutions have $50.5M invested in RVL Pharmaceuticals plc Ordinary Shares in 2022 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 7 closing their positions.
232% more call options, than puts
Call options by funds: $441K | Put options by funds: $133K
127% more capital invested
Capital invested by funds: $22.2M → $50.5M (+$28.3M)
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
21% more funds holding
Funds holding: 38 → 46 (+8)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Athyrium Capital Management
New York
|
+$12.5M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.27M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$537K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$361K |
| 5 |
Millennium Management
New York
|
+$222K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$133K |
| 2 |
Morgan Stanley
New York
|
-$92.4K |
| 3 |
TC
Titleist Capital
San Antonio,
Texas
|
-$39.2K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$37.7K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$34K |
RVLP Hedge Fund Activity: Q3 2022 in Review
46 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q3 2022, worth a combined $50.5M — up 127% from $22.2M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new RVLP positions and 7 closed out — a net gain of 8 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Athyrium Capital Management, adding an estimated $12.5M. The largest seller was Renaissance Technologies, cutting an estimated $133K.
- 46 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q3 2022, up from 38 in Q2 2022.
- Funds reported $50.5M of RVL Pharmaceuticals plc Ordinary Shares stock for Q3 2022, up 127% quarter-over-quarter.
- 15 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q3 2022 and 7 closed out, a net change of +8 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q3 2022 was Athyrium Capital Management, an estimated $12.5M added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q3 2022 was Renaissance Technologies, an estimated $133K sold.
Based on aggregated 13F filings for Q3 2022.